Loading InvisibleSignal...

Clinical Trials Finder

Connecting patients with active research opportunities for infection-associated chronic conditions

Total Trials

Currently Recruiting

Conditions Represented

Search Trials

Condition

Status

Showing 15 of 15 trials

Randomized Controlled Trial of IV Ceftriaxone for Post-Treatment Lyme Disease Syndrome

NCT05891234

Recruiting

Lyme DiseasePhase 3

Baltimore, MD

Enrollment: 300

Mar 2024 – Jun 2027

View on ClinicalTrials.gov

Paxlovid Extended-Course Therapy for Persistent Post-Acute SARS-CoV-2 Symptoms

NCT05923456

Recruiting

Long COVIDPhase 2

Stanford, CA

Enrollment: 450

Jan 2024 – Dec 2026

View on ClinicalTrials.gov

Low-Dose Naltrexone for Fatigue and Cognitive Impairment in Myalgic Encephalomyelitis

NCT05867891

Active

ME/CFSPhase 2

Bethesda, MD

Enrollment: 200

Sep 2023 – Aug 2026

View on ClinicalTrials.gov

Transcranial Magnetic Stimulation for Central Sensitization in Fibromyalgia

NCT05934567

Recruiting

FibromyalgiaPhase 3

Rochester, MN

Enrollment: 250

Jun 2024 – May 2027

View on ClinicalTrials.gov

Ivabradine vs. Propranolol for Heart Rate Control in Postural Orthostatic Tachycardia Syndrome

NCT05876543

Active

POTSPhase 3

Cleveland, OH

Enrollment: 180

Nov 2023 – Nov 2026

View on ClinicalTrials.gov

Omalizumab as Protective Therapy Against Anaphylaxis in Alpha-gal Syndrome

NCT05912345

Recruiting

Alpha-gal SyndromePhase 2

Charlottesville, VA

Enrollment: 120

Apr 2024 – Mar 2027

View on ClinicalTrials.gov

Disulfiram for Borrelia Persister Cells: A Double-Blind Placebo-Controlled Trial

NCT05845678

Active

Lyme DiseasePhase 2

New Haven, CT

Enrollment: 160

Jul 2023 – Jun 2026

View on ClinicalTrials.gov

Metformin for Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection

NCT05956789

Completed

Long COVIDPhase 3

Minneapolis, MN

Enrollment: 1,200

Jun 2022 – Dec 2024

View on ClinicalTrials.gov

BC007 Aptamer Therapy Targeting Autoantibodies in Chronic Fatigue Syndrome

NCT05901234

Recruiting

ME/CFSPhase 1

Berlin, Germany

Enrollment: 60

Sep 2024 – Aug 2026

View on ClinicalTrials.gov

Duloxetine Combined with Aerobic Exercise Program for Fibromyalgia Management

NCT05878901

Completed

FibromyalgiaPhase 4

Philadelphia, PA

Enrollment: 350

Jan 2022 – Jun 2024

View on ClinicalTrials.gov

Autoimmune Biomarker-Guided Immunotherapy for POTS: A Precision Medicine Approach

NCT05943210

Recruiting

POTSPhase 1

Dallas, TX

Enrollment: 80

Aug 2024 – Aug 2027

View on ClinicalTrials.gov

Threshold Dose Determination and Cross-Reactivity Mapping in Alpha-gal Sensitized Patients

NCT05889012

Active

Alpha-gal SyndromePhase 1

Nashville, TN

Enrollment: 90

Oct 2023 – Sep 2026

View on ClinicalTrials.gov

Vagus Nerve Stimulation for Autonomic Dysfunction in Post-Infectious ME/CFS

NCT05967890

Recruiting

ME/CFSPhase 2

Boston, MA

Enrollment: 140

Nov 2024 – Oct 2027

View on ClinicalTrials.gov

NIH RECOVER Platform Trial: Combination Antivirals for Long COVID Viral Persistence

NCT05954321

Recruiting

Long COVIDPhase 2

New York, NY

Enrollment: 900

Feb 2024 – Jan 2027

View on ClinicalTrials.gov

VLA15 Multivalent OspA Lyme Disease Vaccine: Phase 3 Efficacy and Safety

NCT05832109

Active

Lyme DiseasePhase 3

Portland, ME

Enrollment: 6,000

Apr 2023 – Mar 2028

View on ClinicalTrials.gov

Trial listings are for informational purposes. Always discuss participation with your healthcare provider.

Explore Related Modules

Treatment Guide

Evidence-based treatment info

Provider Directory

Find specialists near you

Symptom Screener

Clinical pre-screening tool

Compare Conditions

Side-by-side condition analysis

Data Sources (2)

U.S. National Library of Medicine. ClinicalTrials.gov. 2024.
National Institutes of Health. NIH Clinical Center. 2024.

Clinical Trials Finder

Connecting patients with active research opportunities for infection-associated chronic conditions

Total Trials

Currently Recruiting

Conditions Represented

Search Trials

Condition

Status

Showing 15 of 15 trials

Randomized Controlled Trial of IV Ceftriaxone for Post-Treatment Lyme Disease Syndrome

NCT05891234

Recruiting

Lyme DiseasePhase 3

Baltimore, MD

Enrollment: 300

Mar 2024 – Jun 2027

View on ClinicalTrials.gov

Paxlovid Extended-Course Therapy for Persistent Post-Acute SARS-CoV-2 Symptoms

NCT05923456

Recruiting

Long COVIDPhase 2

Stanford, CA

Enrollment: 450

Jan 2024 – Dec 2026

View on ClinicalTrials.gov

Low-Dose Naltrexone for Fatigue and Cognitive Impairment in Myalgic Encephalomyelitis

NCT05867891

Active

ME/CFSPhase 2

Bethesda, MD

Enrollment: 200

Sep 2023 – Aug 2026

View on ClinicalTrials.gov

Transcranial Magnetic Stimulation for Central Sensitization in Fibromyalgia

NCT05934567

Recruiting

FibromyalgiaPhase 3

Rochester, MN

Enrollment: 250

Jun 2024 – May 2027

View on ClinicalTrials.gov

Ivabradine vs. Propranolol for Heart Rate Control in Postural Orthostatic Tachycardia Syndrome

NCT05876543

Active

POTSPhase 3

Cleveland, OH

Enrollment: 180

Nov 2023 – Nov 2026

View on ClinicalTrials.gov

Omalizumab as Protective Therapy Against Anaphylaxis in Alpha-gal Syndrome

NCT05912345

Recruiting

Alpha-gal SyndromePhase 2

Charlottesville, VA

Enrollment: 120

Apr 2024 – Mar 2027

View on ClinicalTrials.gov

Disulfiram for Borrelia Persister Cells: A Double-Blind Placebo-Controlled Trial

NCT05845678

Active

Lyme DiseasePhase 2

New Haven, CT

Enrollment: 160

Jul 2023 – Jun 2026

View on ClinicalTrials.gov

Metformin for Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection

NCT05956789

Completed

Long COVIDPhase 3

Minneapolis, MN

Enrollment: 1,200

Jun 2022 – Dec 2024

View on ClinicalTrials.gov

BC007 Aptamer Therapy Targeting Autoantibodies in Chronic Fatigue Syndrome

NCT05901234

Recruiting

ME/CFSPhase 1

Berlin, Germany

Enrollment: 60

Sep 2024 – Aug 2026

View on ClinicalTrials.gov

Duloxetine Combined with Aerobic Exercise Program for Fibromyalgia Management

NCT05878901

Completed

FibromyalgiaPhase 4

Philadelphia, PA

Enrollment: 350

Jan 2022 – Jun 2024

View on ClinicalTrials.gov

Autoimmune Biomarker-Guided Immunotherapy for POTS: A Precision Medicine Approach

NCT05943210

Recruiting

POTSPhase 1

Dallas, TX

Enrollment: 80

Aug 2024 – Aug 2027

View on ClinicalTrials.gov

Threshold Dose Determination and Cross-Reactivity Mapping in Alpha-gal Sensitized Patients

NCT05889012

Active

Alpha-gal SyndromePhase 1

Nashville, TN

Enrollment: 90

Oct 2023 – Sep 2026

View on ClinicalTrials.gov

Vagus Nerve Stimulation for Autonomic Dysfunction in Post-Infectious ME/CFS

NCT05967890

Recruiting

ME/CFSPhase 2

Boston, MA

Enrollment: 140

Nov 2024 – Oct 2027

View on ClinicalTrials.gov

NIH RECOVER Platform Trial: Combination Antivirals for Long COVID Viral Persistence

NCT05954321

Recruiting

Long COVIDPhase 2

New York, NY

Enrollment: 900

Feb 2024 – Jan 2027

View on ClinicalTrials.gov

VLA15 Multivalent OspA Lyme Disease Vaccine: Phase 3 Efficacy and Safety

NCT05832109

Active

Lyme DiseasePhase 3

Portland, ME

Enrollment: 6,000

Apr 2023 – Mar 2028

View on ClinicalTrials.gov

Trial listings are for informational purposes. Always discuss participation with your healthcare provider.

Explore Related Modules

Treatment Guide

Evidence-based treatment info

Provider Directory

Find specialists near you

Symptom Screener

Clinical pre-screening tool

Compare Conditions

Side-by-side condition analysis

Data Sources (2)

U.S. National Library of Medicine. ClinicalTrials.gov. 2024.
National Institutes of Health. NIH Clinical Center. 2024.